A 45-year-old woman with newly diagnosed AML and a FLT3-ITD mutation who develops differentiation syndrome
A 45-year-old woman is diagnosed with acute myeloid leukemia. Cytogenetics show a normal karyotype, and molecular testing shows a FLT3-ITD mutation with a high allelic ratio, NPM1 mutation, and no IDH1/2 or TP53 mutations. She is started on induction with cytarabine and daunorubicin plus midostaurin. On day 12 she develops fever, weight gain of 4 kg, bilateral pulmonary infiltrates, and a rising white count with peripheral blasts. She is hypoxic with an oxygen saturation of 90% on room air. Blood cultures are negative. She asks what is happening and whether the midostaurin should be stopped.
1. What is the likely diagnosis, and how would you manage it?
Read the worked answer
The likely diagnosis is differentiation syndrome (formerly retinoic acid syndrome), a known complication of FLT3 inhibitors such as midostaurin, particularly during induction.
Reasoning:
- Fever, weight gain, pulmonary infiltrates, hypoxia, and a rising white count with blasts are classic.
- Management: start dexamethasone 10 mg IV every 12 hours (or equivalent) promptly; hold midostaurin temporarily; provide oxygen and supportive care; monitor for renal and hepatic dysfunction. Diuretics may be used cautiously for fluid overload.
- Differentiation syndrome can be life-threatening, so empiric broad-spectrum antibiotics should be given until infection is excluded.
- Once symptoms improve, midostaurin can often be resumed at the same or reduced dose with continued steroids and close monitoring.
- Hydroxyurea may be used for hyperleukocytosis.
2. What is the role of FLT3-ITD testing in her prognosis and treatment?
Read the worked answer
FLT3-ITD is a poor-risk marker, especially with a high allelic ratio.
- Prognosis: FLT3-ITD with a high allelic ratio confers a higher relapse risk and shorter survival; the NPM1 co-mutation modifies but does not eliminate this risk.
- Treatment: Addition of a FLT3 inhibitor (midostaurin) to standard 7+3 induction and consolidation improves overall survival in FLT3-mutated AML. After consolidation, allogeneic hematopoietic stem cell transplantation should be strongly considered in first remission for high-risk disease.
- Monitoring: Serial molecular testing (e.g., NPM1 transcript or FLT3-ITD) can detect measurable residual disease and guide decisions about transplant.
- Later lines: Gilteritinib is approved for relapsed/refractory FLT3-mutated AML.
3. What would you tell her about the expected course and the role of transplant?
Read the worked answer
Counseling points:
- Induction typically requires 4–6 weeks of hospitalization, with a risk of infection, mucositis, and cytopenias.
- Differentiation syndrome is treatable but requires prompt recognition; she should report fever, weight gain, or shortness of breath immediately.
- If she achieves remission, consolidation and allogeneic transplant offer the best chance of long-term disease control given her high-risk FLT3-ITD status.
- Transplant carries risks of graft-versus-host disease, infection, and treatment-related mortality, and requires a suitable donor and good performance status.
- Maintenance with an FLT3 inhibitor after transplant may be considered in some settings.
- Shared decision-making and psychosocial support are important.